Search

Displaying results 1901 - 1910 of 5263 in total
  1. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D.

  2. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Pipradrol (Meratran) was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international regulation . Pipradrol was made illegal ...

  3. Drug

    Phenytoin

    go.drugbank.com/drugs/DB00252
    ApprovedInvestigationalVet approved

    [A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications … [A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal

  4. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

  5. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. … It contains 6 N-linked oligosaccharide modification sites.

  6. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].

  7. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administ...

  8. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.

  9. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label]. … Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide
  10. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)